Brief: Crispr Therapeutics says FDA Accepted Biologics License Application For Exa-Cel

Crispr Therapeutics AG

09/06/2023 13:21

June 9 (Reuters) - CRISPR Therapeutics AG  CRSP.BN :
    * CRISPR THERAPEUTICS - ON JUNE 8, CO, VERTEX SAID FDA
ACCEPTED
BLAS FOR EXA-CEL, BEING INVESTIGATED FOR TREATMENT OF SCD, TDT
IN PATIENTS AGES 12 TO 35
    * CRISPR THERAPEUTICS - ALL PATIENTS TREATED WITH EXA-CEL
SHOWED
CLINICAL BENEFIT, DATA CONTINUE TO SHOW POTENTIALLY
TRANSFORMATIVE PROFILE OF EXA-CEL
    * CRISPR THERAPEUTICS- SAFETY PROFILE OF EXA-CEL CONSISTENT
WITH
MYELOABLATIVE CONDITIONING WITH BUSULFAN, AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANT
    * CRISPR THERAPEUTICS - BOTH CLIMB-111 AND CLIMB-121 MET
PRIMARY
ENDPOINT AND KEY SECONDARY ENDPOINT AT PRE-SPECIFIED INTERIM
ANALYSIS FOR EACH TRIAL

Further company coverage:  CRSP.BN 

 (reuters.briefs@thomsonreuters.com)